News|Videos|November 20, 2026

Valbenazine Improves Patient-Reported Tardive Dyskinesia Impacts in KINECT-PRO Post Hoc Analysis

Most patients taking valbenazine reported meaningful relief from how tardive dyskinesia affects daily life, with gains across social, emotional, and physical domains.

A post hoc analysis of the phase 4 KINECT-PRO study shows most patients with tardive dyskinesia (TD) treated with valbenazine (Ingrezza) reported clinically meaningful improvement in the condition’s impact on daily life, according to Neurocrine Biosciences.

Valbenazine is a once-daily vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release, which is thought to drive the involuntary movements of TD. KINECT-PRO was a 24-week, open-label study with patient-reported outcomes as its primary endpoints. Participants received valbenazine 40, 60, or 80 mg once daily.1

The analysis focused on the Tardive Dyskinesia Impact Scale (TDIS). This 11-item patient-reported measure has a total score range of 0 to 44 and captures the physical, social, and emotional impacts of TD. A minimal clinically important difference (MCID) of 4 points was established earlier through anchor-based analyses of KINECT 3 and KINECT 4 data.2

About 6 in 10 participants met the TDIS MCID, and 82% reported any improvement in TD impact. Investigators also looked at item groupings that reflect the patient experience: socialization, emotionality, pain, dexterity, and mouth and throat function.

TD symptoms can wax and wane, and they affect different body regions in different patients. Improvement below the MCID threshold may therefore still matter to an individual patient. Clinicians should assess each patient individually and revisit treatment goals over time.

“It’s really nice that the [TDIS] brings the patient voice into the conversation about the impact of those movements,” said Morgan Bron, PharmD, MS, senior director of health economics and outcomes research in Medical Affairs at Neurocrine Biosciences.

Next, Neurocrine plans to study what drives improvement in this population. It will look at patient-reported outcomes, clinician-reported outcomes, and efficacy measures.

Dr Bron is the health economics and outcomes research senior director at Neurocrine.

References

1. Correll CU, Perez-Rodriguez MM, McEvoy JP, et al. Valbenazine improves quality of life, functionality, and movement severity in patients with tardive dyskinesia: findings from the KINECT-PRO™ study. CNS Spectr. 2026:e30.

2. Bron M, Mathias S, Gao S, et al. Estimation of the minimal clinically important difference (MCID) and longitudinal change in the Tardive Dyskinesia Impact Scale (TDIS), a validated, tardive dyskinesia-specific, patient-reported outcome measure. Poster presented at: Psych Congress Elevate 2025; September 17-21, 2025; San Diego, California.


Related to this article